C4 Therapeutics, Inc. (CCCC) stock
CCCCNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 5, 2026Score 9/302% below fair value
$2.53−0.12 (-4.53%)
Close on Nov 17, 2026Market cap $311.25MP/E –Yield –
C4 Therapeutics revenue
Revenue is the money a company takes in from selling its products and services, before any costs are deducted.
C4 Therapeutics's revenue for the twelve months ending Jun 30, 2026 was $35.04M, up 2.3% year over year. For fiscal 2025 it was $35.95M, up 1.0% from the year before. The highest annual figure on record is $45.79M in fiscal 2021.
Annual revenue
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $35.95M | +1.0% |
| FY2024 | Dec 31, 2024 | $35.58M | +71.4% |
| FY2023 | Dec 31, 2023 | $20.76M | -33.3% |
| FY2022 | Dec 31, 2022 | $31.10M | -32.1% |
| FY2021 | Dec 31, 2021 | $45.79M | – |
Quarterly revenue
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $6.64M | +2.8% |
| Q1 FY2026 | Mar 31, 2026 | $6.15M | -15.0% |
| Q4 FY2025 | Dec 31, 2025 | $11.02M | +112.8% |
| Q3 FY2025 | Sep 30, 2025 | $11.23M | -26.9% |
| Q2 FY2025 | Jun 30, 2025 | $6.46M | -46.2% |
| Q1 FY2025 | Mar 31, 2025 | $7.24M | +138.2% |
| Q4 FY2024 | Dec 31, 2024 | $5.18M | +58.8% |
| Q3 FY2024 | Sep 30, 2024 | $15.36M | +38.7% |
| Q2 FY2024 | Jun 30, 2024 | $12.01M | +350.7% |
| Q1 FY2024 | Mar 31, 2024 | $3.04M | -19.2% |
| Q4 FY2023 | Dec 31, 2023 | $3.26M | +14.3% |
| Q3 FY2023 | Sep 30, 2023 | $11.07M | +63.9% |
| Q2 FY2023 | Jun 30, 2023 | $2.66M | -80.7% |
| Q1 FY2023 | Mar 31, 2023 | $3.76M | -50.9% |
| Q4 FY2022 | Dec 31, 2022 | $2.85M | -85.8% |
| Q3 FY2022 | Sep 30, 2022 | $6.75M | -20.5% |
| Q2 FY2022 | Jun 30, 2022 | $13.83M | +41.4% |
| Q1 FY2022 | Mar 31, 2022 | $7.65M | – |
| Q4 FY2021 | Dec 31, 2021 | $20.08M | – |
| Q3 FY2021 | Sep 30, 2021 | $8.50M | – |
| Q2 FY2021 | Jun 30, 2021 | $9.78M | – |
See a number that looks wrong?